Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12050814 | 0.87 | BCHE (0.53) | BCHEACHENPY5ROPRK1MAOB | |
| SCHEMBL9649858 | 0.86 | BCHE (0.42) | ACACBBCHEACHENPY5RMAOB | |
| SCHEMBL9650269 | 0.83 | CYP4F2 (0.43) | ACACBBCHEACHENPY5RPPARG | |
| SCHEMBL25173080 | 0.83 | PPARG (0.40) | PPARGPPARAAAK1 | |
| SCHEMBL13748638 | 0.83 | ALOX15 (0.49) | BCHEACHEOPRK1PPARGAAK1 | |
| SCHEMBL11235133 | 0.81 | HSD17B10 (0.43) | BCHEACHEOPRM1OPRD1OPRK1 | |
| SCHEMBL8476620 | 0.80 | MAPT (0.42) | BCHEACHE | |
| SCHEMBL7603010 | 0.80 | MAPT (0.42) | BCHEACHE | |
| SCHEMBL21626010 | 0.79 | ALDH1A1 (0.44) | BCHEACHEOPRK1PPARGAAK1 | |
| SCHEMBL7603004 | 0.79 | PTGS1 (0.41) | ACACBBCHEACHENPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039009-B1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2019-05-01 | — | — | EP | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | ACACB 125/4885BCHE 1448/4885ACHE 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.